52.1% of Global Active Pharmaceutical Ingredients (API) Market Revenue is generated by Innovative Active Pharmaceutical Ingredients

 

 According to the World Health Organization (WHO), cardiovascular diseases are the most significant cause of death worldwide, according to the World Health Organization (WHO), resulting in the deaths of 17.9 million people each year. The active pharmaceutical ingredient (API) is the substance that makes a medicine work. API is a component of any medicine that generates the desired effects. Drugs are frequently made up of multiple ingredients. The API is the most important component. Excipients are other components that must be biologically innocuous and typically form a changing fraction of the medication composition. Formulation refers to the process of optimizing and composing the mixture of components used in medicine.

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-active-pharmaceutical-ingredient-api-market

Data Bridge Market Research analyses that the active pharmaceutical ingredients (API) market is expected to grow at a CAGR of 7.1% in the forecast period of 2021 to 2028 and is expected to reach USD 300,722.26 million by 2028. The rising initiatives by public and private organizations to spread awareness will expand the active pharmaceutical ingredients (API) market. Furthermore, rising adoption rate of organ on chip models in drug development and rising focus on precision medicine will result in the expansion of active pharmaceutical ingredients (API) market.

Active Pharmaceutical Ingredients (API) Market

Rising prevalence of chronic diseases is expected to drive the market's growth rate during the forecast period.

The rising prevalence of chronic diseases such as Alzheimer's disease and others is estimated to enhance the growth of the active pharmaceutical ingredients (API) market. As per the Alzheimer's Association, 5.8 million people in the United States were living with Alzheimer's disease in 2020. This disease is the sixth biggest cause of death in the United States, and it is more common in persons over the age of 65. This number is likely to rise to 14 million as the baby-boomer generation reaches retirement age, aggravating the situation throughout the projection period. A new case of the disease is predicted to emerge every 33 seconds by 2050.

Report Scope and Market Segmentation

Report Metric

Details

Forecast Period

2021 to 2028

Base Year

2020

Historic Years

2019 (Customizable to 2013 - 2018)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Molecule (Small Molecule, Large Molecule), Type (Innovative Active Pharmaceutical Ingredients, Generic Innovative Active Pharmaceutical Ingredients), Type of Manufacturer (Captive API Manufacturer, Merchant API Manufacturer), Chemical Synthesis (Acetaminophen, Artemisinin, Saxagliptin, Sodium Chloride, Ibuprofen, Losartan Potassium, Enoxaparin Sodium, Rufinamide, Naproxen, Tamoxifen, Others), Type of Drug (Prescription Drugs, Over-the-Counter), Usage (Clinical, Research), Potency (Low-to-Moderate Potency Active Pharmaceutical Ingredients, Potent-to-Highly Potent Active Pharmaceutical Ingredient), Therapeutic Application (Cardiology, CNS and Neurology, Oncology, Orthopedic, Endocrinology, Pulmonology, Gastroenterology, Nephrology, Ophthalmology, Other Therapeutic Application)

Countries Covered

U.S., Canada, Mexico, Germany, France, Italy, U.K., Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Luxembourg , Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific , Brazil, Argentina, Peru, Rest of South America, Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt, Rest of Middle East & Africa

Market Players Covered

Pfizer Inc. (U.S.), Sun Pharmaceutical Industries Ltd. (India), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Dr. Reddy's Laboratories Ltd. (India), Merck KGaA (Germany),  Novo Nordisk A/S (Denmark), Alembic Pharmaceuticals Limited (India), AbbVie Inc. (U.S.), Aurobindo Pharma (India), Lupin (India), AARTI INDUSTRIES LIMITED (India), Recipharm AB (Sweden), Jubilant Pharmova Limited (India), AstraZeneca (U.K.), Novartis AG (Switzerland), BASF SE (Germany), Cipla Inc. (U.S.), Alkem Labs (India), Albemarle Corporation (U.S.), Saneca Pharmaceuticals (Slovakia), Unichem Laboratories (India), Neuland Laboratories Ltd. (India), Divi's Laboratories Limited (India), HIKAL Ltd. (India), Viatris Inc. (U.S.)

Data Pointers Covered in Report

In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Segment Analysis:

The active pharmaceutical ingredients (API) market is segmented on the basis of molecule, type, type of manufacturer, synthesis, chemical synthesis, type of drug, usage, potency and therapeutic application.

  • On the basis of molecule, global active pharmaceutical ingredients (API) market is segmented into small molecule and large molecule. In 2021, the small molecule segment is expected to dominate the market with 63.78%market share due to increasing regulatory approval and rising research and development on novel small molecules due to their high penetration power.

In 2021, the small molecule segment of molecule segment is anticipated to dominate the active pharmaceutical ingredients (API) market

In 2021, the small molecule segment of this market will dominate the active pharmaceutical ingredients (API) market due to increasing number of regulatory approval and rising research and development on novel small molecules due to their high penetration power. The small molecule segment is expected reach the highest CAGR of 7.3% in the forecast period of 2021-2028.

  • On the basis of type, global active pharmaceutical ingredients (API) market is segmented into innovative active pharmaceutical ingredients and generic active pharmaceutical ingredients. In 2021, innovative active pharmaceutical ingredients segment is expected to dominate the market with 52.17% market share because of the high cost of innovative APIs compared to generic APIs and rising FDA approval for the new molecular entities.
  • On the basis of type of manufacturer, global active pharmaceutical ingredients (API) market is segmented into captive API manufacturer and merchant API manufacturer. In 2021, captive API manufacturer segment is expected to dominate the market with 61.29% market share due to huge investment by major market players to generate high end manufacturing facilities and easy availability of raw materials.
  • On the basis of synthesis, global active pharmaceutical ingredients (API) market is segmented into synthetic active pharmaceutical ingredients and biotech active pharmaceutical ingredients. In 2021, the synthetic active pharmaceutical ingredients segment is expected to dominate the market with 57.47% market share because of easy protocol for the synthesis of molecules, less stringent regulatory guidelines, and many synthetic molecules going off patent in the coming years.
  • On the basis of chemical, global active pharmaceutical ingredients (API) market is segmented into acetaminophen, artemisinin, saxagliptin, sodium chloride, ibuprofen, losartan potassium, enoxaparin sodium, rufinamide, naproxen, tamoxifen, and others. In 2021, saxagliptin segment is expected to dominate the market with 11.76% market share due to high cost of the API and rising diabetes cases worldwide.
  • On the basis of type of drug, global active pharmaceutical ingredients (API) market is segmented into prescription drugs and over-the-counter drugs. In 2021, the prescription drugs segment is expected to dominate the market with 53.26% market share because of the high cost of the drugs, which will increase the APIs and manufacturing cost.
  • On the basis of usage, the global active pharmaceutical ingredients (API) market is segmented into clinical and research. In 2021, the clinical segment is expected to dominate the market with 66.32% market share because of the rising number of diseases requiring continuous supply of APIs and raw material.

In 2021, the clinical segment is projected to hold the largest share of usage segment in the active pharmaceutical ingredients (API) market

In 2021, the clinical segment is anticipated to hold the largest share of global active pharmaceutical ingredients (API) market because of rising number of diseases which required continuous supply of APIs and raw material. The clinical segment is growing with a CAGR of 7.6% in the forecast period of 2021 to 2028.

  • On the basis of potency, global active pharmaceutical ingredients (API) market is segmented into low-to-moderate potency active pharmaceutical ingredients and potent-to-highly potent active pharmaceutical ingredient. In 2021, hospital pharmacy segment is expected to dominate the market with 56.52% market share because of their less toxicity and less hazard nature.
  • On the basis of therapeutic application, global active pharmaceutical ingredients (API) market is segmented into cardiology, CNS & neurology, oncology, orthopedic, endocrinology, pulmonology, gastroenterology, nephrology, ophthalmology, and other therapeutic application. In 2021, hospital pharmacy segment is expected to dominate the market with 19.05% market share because of rising number of cardiac diseases such as heart attack, embolism and others. 

Major Players

Data Bridge Market Research recognizes the following companies as the major Pfizer Inc. (U.S.), Sun Pharmaceutical Industries Ltd. (India), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Dr. Reddy's Laboratories Ltd. (India), Merck KGaA (Germany),  Novo Nordisk A/S (Denmark), Alembic Pharmaceuticals Limited (India), AbbVie Inc. (U.S.).

Active Pharmaceutical Ingredients (API) Market

Market Development

  • In August 2021, Teva Pharmaceutical and MEDinCell had received US Food and Drug Administration (FDA) approval for their New Drug Application of TV-46000/mdc-IRM (risperidone extended-release injectable suspension for subcutaneous use). The approval is based on Phase 3 results from two pivotal studies: TV46000-CNS-30072 (The Risperidone Subcutaneous Extended-Release Study) and TV46000-CNS-30078 (A Study to Test whether TV-46000 is Safe for Schizophrenia Maintenance Treatment). These trials looked at the efficacy, long-term safety, and tolerance of TV-46000 as a schizophrenia treatment.
  • In December 2021, Novasep, a provider of services and solutions to the life sciences industry, invested roughly EUR 6 million in its Chasse-sur-Rhône, France, location to expand its capabilities in areas including oncology, the central nervous system (CNS), and infectious diseases.
  • In August 2020, Pfizer Inc. announced their partnership with Gilead Sciences Inc. to manufacture and supply Gilead's investigational antiviral remdesivir supporting efforts to scale up the supply of the investigational treatment for COVID-19. Pfizer will produce and supply remdesivir for Gilead under the terms of the agreement, which will be carried out at Pfizer's McPherson, Kansas facility.
  • In May 2020, Boehringer Ingelheim announced the acquisition of Northern Biologics' Preclinical Cancer Antibody Pipeline, expanding immuno-oncology portfolio. Boehringer Ingelheim has positioned itself at the forefront of the stromal biology field, an emerging topic in cancer immunology, by acquiring this company, which focuses on therapeutic antibodies targeting the tumor microenvironment. Northern Biologics will keep its brand and continue to drive preclinical work on one of the products, while Boehringer Ingelheim will be in charge of the acquired programs' clinical, regulatory, and commercial development.

Regional Analysis

Geographically, the countries covered in the Active pharmaceutical ingredients (API) market report are U.S., Canada, Mexico, Germany, France, Italy, U.K., Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Luxembourg , Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific , Brazil, Argentina, Peru, Rest of South America, Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt, Rest of Middle East & Africa.

As per Data Bridge Market Research analysis:

North America is the dominant region in Active pharmaceutical ingredients (API) market during the forecast period 2021 - 2028

North America will continue to dominate the Active pharmaceutical ingredients (API) market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period due to the increasing incidences of disease and rising geriatric population in this region. U.S. is estimated to dominate the North American region because of increasing healthcare expenditure and well-established healthcare infrastructure in this region.

Asia-Pacific is estimated to be the fastest-growing region in Active pharmaceutical ingredients (API) market the forecast period 2021 - 2028

Asia-Pacific region is anticipated to grow at the highest rate during the forecast period of 2021-2028 due to the rising healthcare expenditure and presence of major key players in the region. China is anticipated to dominate the Asia-Pacific region due to increase in availability of active pharmaceutical ingredients (API) at lower cost.

COVID-19 Impact Analysis

The global increase in COVID-19 instances has influenced the development of active pharmaceutical ingredient producers over the projection period. In India's active pharmaceutical ingredient market, the government has finished a molecule-by-molecule charting of APIs supplied from China in order to boost domestic construction and imports from third-party providers in light of the COVID-19 pandemic's supply chain disruptions. The administration is organizing special provisions for APIs that must still be supplied from China.

The COVID-19 outbreak hampered several strategic pharmaceutical businesses' manufacturing and supply chains. The worldwide active pharmaceutical ingredient market model is expected to be impacted significantly by China's reliance on APIs for various biologics and generic pharmaceuticals. During the Chinese government's pandemic lockdown measures, around 44 enterprises were deemed invalid. This tendency has largely contributed to countries implementing local API manufacturing programs after re-evaluating their healthcare models in order to cure the infection and ensure a stable influx of API production.

For more detailed information about the Active pharmaceutical ingredients (API) market report, click here –https://www.databridgemarketresearch.com/reports/global-active-pharmaceutical-ingredient-api-market